Navigation Links
Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Date:6/4/2009

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • 8th Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 9:00 a.m. Eastern Time at the New York Palace Hotel in New York City.
  • Jefferies' 3rd Annual Healthcare Conference on Thursday, June 18, 2009 at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel in New York City.
  • Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 3:00 p.m. British Summer Time (8:00 a.m. Eastern Time) at the ANdAZ Hotel in London.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
2. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Bangkok, Thailand (PRWEB) , ... May 25, 2016 ... ... the participation of a Thai delegation at BIO 2016 in San Francisco. Located ... private sector will be available to answer questions and discuss the Thai biotechnology ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the use ... W. Stellar has been named by the WEDI Board of Directors as WEDI’s president ... executive leader with more than 35 years of experience in healthcare, association management and ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... 23, 2016 Oxitec CEO Hadyn ... at 10:15 a.m. ET before the United States House Committee ... mosquitos can play in controlling the spread of the ... virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... a self-limiting gene. Trials in Brazil , ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):